drugset
drugset / Trial / NCT03182673

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

NCT03182673 ↗

Phase 1 Terminated 31 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study consists of the two parts, the first one is SHR7390 combined with SHR-1210, the second one is SHR7390 combined with SHR-1210 and SHR3162. Two parts of the study are separately to assess the safety and tolerability, to define dose limiting toxicity（DLT) and maximum tolerated dose (MTD),to evaluate the pharmacokinetics ,to assess the antitumor activity in patients with advanced solid tumors preliminarily and to recommend reasonable dosage regimen of SHR7390 for the follow-up clinical trial.

Timeline

Start
2017-07-24
Primary completion
2019-06-12
Completion
2019-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Fluzoparib Small molecule 10 mg Oral
Subject Fluzoparib Small molecule 40 mg Oral
Subject Fluzoparib Small molecule 100 mg Oral
Subject SHR7390 Unknown 0.125 mg Oral
Subject SHR7390 Unknown 0.5 mg Oral
Subject SHR7390 Unknown 2 mg Oral
Subject SHR7390 Unknown 4 mg Oral

Indications

cancer